Daxor Corporation Announces That PCI Nuclear Pharmacy Acquires BVA-100 Blood Volume Analyzer

NEW YORK, NY--(Marketwire - November 19, 2012) -

Daxor Corporation (NYSE MKT: DXR), a medical instrumentation and biotechnology company, today announced the receipt of a signed trial agreement from PCI Nuclear Pharmacy in Arizona. This agreement will provide PCI with a Daxor BVA-100 Blood Volume Analyzer, an instrument which enables semi-automated measurement of a patient’s total blood volume, red blood cell volume and plasma volume. Blood volume abnormalities are observed in a variety of cardiac conditions and have been associated with poor prognosis. Published studies using the BVA-100 have shown that blood volume measurement is important in treating heart failure, critical care patients in intensive care units, and in diagnosing the true status of complex anemias and syncope (fainting).

PCI Nuclear Pharmacy is a privately owned leading provider of unit dose radiopharmaceuticals, custom compounding and ancillary products used in nuclear medicine. The parent company, Arizona Home Care has been operating since 1996. The radiopharmacy was started in 2007. The combination of a nuclear pharmacy, infusion pharmacy and home care services, is designed to comprehensively fit the needs of Arizona’s patients and their health care providers. The pharmacy professionals provide the expertise necessary to offer these pharmaceutical specialties to a very active and patient-oriented community in Phoenix and Tucson, AZ. The pharmacy professionals provide the expertise necessary to offer these specialties to the Phoenix and Tucson communities serving hospitals, clinics, skilled nursing facilities and patients in their homes.

Ridge Smidt, Managing Member of PCI Nuclear/ Patient Care Infusion, said, “We are very pleased to be able to begin to provide this valuable service to the hospitals in the community.”

Dr. Joseph Feldschuh, President of Daxor, said that “The model of nuclear pharmacies providing blood volume measurement services is one that offers the potential for many more hospitals that do not have a nuclear medicine department to provide this essential valuable service to patients.”

Daxor Corporation manufactures and markets the BVA-100, which is used in conjunction with Volumex, Daxor’s single use diagnostic kit. For more information regarding Daxor Corporation’s Blood Volume Analyzer BVA-100, visit Daxor’s website at www.Daxor.com.